Spurious hyperphosphatemia in a patient with alteplase-locked central venous catheter.
Alteplase has been shown to be effective in preventing central venous access clotting in patients on hemodialysis. Because of a high phosphorus content in its excipient, it can inadvertently contaminate blood samples, leading the physician in care of the patient to erroneously increase dialysis time or change diet in order to control the pseudo-hyperphosphatemia.
Cachat
Francois
F
Bardy
Daniel
D
Durussel
Claudine
C
Di Paolo
Ermindo
E
D002405:Catheterization, Central Venous / Q000295:instrumentation*; D002675:Child, Preschool; D005343:Fibrinolytic Agents / Q000009:adverse effects*; D006801:Humans; D008297:Male; D010760:Phosphorus Metabolism Disorders / Q000139:chemically induced*; D006435:Renal Dialysis / Q000295:instrumentation*; D010959:Tissue Plasminogen Activator / Q000009:adverse effects*
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator